Wenxin Xu

Apr 5, 2024 | onclive.com | Wenxin Xu

Wenxin (Vincent) Xu, MD, physician, Dana-Farber Cancer Institute, and assistant professor of medicine, Harvard Medical School, discusses ongoing efforts to identify emerging biomarkers in metastatic renal cell carcinoma (RCC). The ongoing phase 2 OPTIC RCC trial (NCT05361720) is assessing the use of established biologic clusters to guide selection between an immuno-oncology (IO) and TKI approach vs an IO/IO regimen for patients with clear cell RCC, Xu begins.

Mar 27, 2024 | onclive.com | Wenxin Xu

Wenxin (Vincent) Xu, MD, physician, Dana-Farber Cancer Institute, assistant professor, medicine, Harvard Medical School, highlights ongoing research in patients with renal cell carcinoma (RCC), spotlighting significant developments and emerging updates in patients with non–clear cell RCC (ccRCC). Recent developments in RCC offer promising avenues for improved patient outcomes, Xu begins.

Mar 26, 2024 | onclive.com | Wenxin Xu

Wenxin (Vincent) Xu, MD, physician, Dana-Farber Cancer Institute, and assistant professor of medicine, Harvard Medical School,provides insights into the rapid evolution of systemic therapy for patients with renal cell carcinoma (RCC), marked by significant developments and emerging treatment modalities.

Mar 22, 2024 | onclive.com | Wenxin Xu

March 22, 2024Wenxin (Vincent) Xu, MD, discusses treatment decision-making in patients with renal cell carcinoma. Wenxin (Vincent) Xu, MD, physician, Dana-Farber Cancer Institute, assistant professor, medicine, Harvard Medical School, discusses treatment decision-making for patients with renal cell carcinoma (RCC), highlighting how he approaches treatment upon disease progression for patients in this population.

Mar 9, 2024 | onclive.com | Wenxin Xu

March 9, 2024Wenxin (Vincent) Xu, MD, discusses the factors he takes into account when sequencing treatment options for patients with metastatic renal cell carcinoma. Wenxin (Vincent) Xu, MD, physician, Dana-Farber Cancer Institute, and assistant professor of medicine, Harvard Medical School, discusses the factors he takes into account when sequencing treatment options for patients with metastatic renal cell carcinoma (RCC).